uniQure (NASDAQ:QURE) Shares Down 4.8% – Here’s Why

Shares of uniQure (NASDAQ:QURE) fell 4.8% during trading on Tuesday . The company traded as low as $15.08 and last traded at $15.05. 74,702 shares traded hands during trading, a decline of 93% from the average session volume of 1,144,552 shares. The stock had previously closed at $15.80.

Analysts Set New Price Targets

QURE has been the topic of several research reports. Stifel Nicolaus boosted their price objective on shares of uniQure from $12.00 to $32.00 and gave the stock a “buy” rating in a report on Monday, December 16th. The Goldman Sachs Group upped their target price on uniQure from $9.00 to $20.00 and gave the company a “neutral” rating in a research note on Thursday, December 12th. Wells Fargo & Company raised shares of uniQure from a “hold” rating to a “strong-buy” rating in a report on Tuesday, December 10th. Leerink Partners raised their price objective on shares of uniQure from $26.00 to $44.00 and gave the stock an “outperform” rating in a report on Wednesday, December 11th. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $24.00 target price on shares of uniQure in a research note on Tuesday, January 21st. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, six have issued a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $40.00.

uniQure Stock Down 4.1 %

The firm has a fifty day moving average price of $12.93 and a 200 day moving average price of $8.74. The company has a quick ratio of 6.51, a current ratio of 6.51 and a debt-to-equity ratio of 0.92. The company has a market cap of $738.65 million, a P/E ratio of -3.06 and a beta of 0.41.

uniQure (NASDAQ:QURE) last issued its earnings results on Tuesday, November 5th. The biotechnology company reported ($0.91) EPS for the quarter, beating the consensus estimate of ($1.12) by $0.21. The firm had revenue of $2.29 million during the quarter, compared to the consensus estimate of $2.73 million. uniQure had a negative net margin of 837.80% and a negative return on equity of 188.82%. Equities research analysts forecast that uniQure will post -3.74 earnings per share for the current year.

Insider Buying and Selling

In other uniQure news, CEO Matthew C. Kapusta sold 3,418 shares of uniQure stock in a transaction dated Monday, December 9th. The stock was sold at an average price of $7.63, for a total value of $26,079.34. Following the sale, the chief executive officer now owns 597,915 shares of the company’s stock, valued at $4,562,091.45. This trade represents a 0.57 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 4.74% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On uniQure

Several institutional investors and hedge funds have recently added to or reduced their stakes in QURE. China Universal Asset Management Co. Ltd. increased its position in shares of uniQure by 9.6% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 11,062 shares of the biotechnology company’s stock valued at $195,000 after acquiring an additional 969 shares during the last quarter. Sanders Morris Harris LLC grew its stake in shares of uniQure by 50.0% in the fourth quarter. Sanders Morris Harris LLC now owns 102,104 shares of the biotechnology company’s stock valued at $1,803,000 after buying an additional 34,034 shares in the last quarter. FNY Investment Advisers LLC acquired a new position in uniQure during the fourth quarter worth $88,000. Franklin Resources Inc. acquired a new position in uniQure during the third quarter worth $7,360,000. Finally, Geode Capital Management LLC raised its position in uniQure by 1.3% during the third quarter. Geode Capital Management LLC now owns 508,602 shares of the biotechnology company’s stock worth $2,509,000 after acquiring an additional 6,362 shares in the last quarter. 78.83% of the stock is owned by institutional investors.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.